Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
University of Michigan Rogel Cancer Center
University of Pittsburgh
Memorial Sloan Kettering Cancer Center
University of Pittsburgh
Medical University of South Carolina
Hookipa Biotech GmbH
Incyte Corporation
Incyte Corporation
Bristol-Myers Squibb
Dana-Farber Cancer Institute
University of Chicago
University of Chicago
Thomas Jefferson University
Thomas Jefferson University
Bayer
Bristol-Myers Squibb
UNICANCER
University of Pittsburgh
Purple Biotech Ltd.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Astellas Pharma Inc
Dana-Farber Cancer Institute
Emory University
Compugen Ltd
UNICANCER
Rutgers, The State University of New Jersey
The Netherlands Cancer Institute
Bayer
Bristol-Myers Squibb
University Health Network, Toronto
Tempest Therapeutics
Bristol-Myers Squibb
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
RTOG Foundation, Inc.
AIO-Studien-gGmbH
Bristol-Myers Squibb
Incyte Corporation
Bristol-Myers Squibb
Genocea Biosciences, Inc.
Memorial Sloan Kettering Cancer Center
Five Prime Therapeutics, Inc.
UNICANCER
Akamis Bio
Bristol-Myers Squibb
Oncovir, Inc.
Osaka University
Celldex Therapeutics